LPCN · Company research
Lipocine Inc. (LPCN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Press Releases about Lipocine Inc. - Common Stock (Nasdaq:LPCN) - FinancialContent | Press Releases about Lipocine Inc. - Common Stock (Nasdaq:LPCN) FinancialContent | View source ↗ | FinancialContent | Oct 10, 2026 | neutral | 0 | 0.6 |
| Lipocine Inc. (LPCN) stock price, news, quote and history - Yahoo Finance Singapore | Lipocine Inc. (LPCN) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 9, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now - TradingView | Here's Why You Should Add LPCN Stock to Your Portfolio Now TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| Lipocine’s TLANDO Wins Health Canada Approval - The Globe and Mail | Lipocine’s TLANDO Wins Health Canada Approval The Globe and Mail | View source ↗ | The Globe and Mail | Oct 8, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now - Yahoo Finance | Here's Why You Should Add LPCN Stock to Your Portfolio Now Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off - StocksToTrade | LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off StocksToTrade | View source ↗ | StocksToTrade | Oct 7, 2026 | neutral | 0 | 0.6 |
| Why Is Lipocine Stock Soaring Today? - Lipocine (NASDAQ:LPCN) - Benzinga | Why Is Lipocine Stock Soaring Today? - Lipocine (NASDAQ:LPCN) Benzinga | View source ↗ | Benzinga | Oct 7, 2026 | neutral | 0 | 0.6 |
| LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off - Timothy Sykes | LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off Timothy Sykes | View source ↗ | Timothy Sykes | Oct 7, 2026 | neutral | 0 | 0.6 |
| LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today - Stocktwits | LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today - Yahoo Finance | LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off - StocksToTrade | LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off StocksToTrade | View source ↗ | StocksToTrade | Oct 7, 2026 | neutral | 0 | 0.6 |
| Canada approves a testosterone pill for men, with launch planned by year-end. - Stock Titan | Canada approves a testosterone pill for men, with launch planned by year-end. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| A 48-hour home treatment for postpartum depression enters a new study. About 120 participants are planned. - Stock Titan | A 48-hour home treatment for postpartum depression enters a new study. About 120 participants are planned. Stock Titan | View source ↗ | Stock Titan | Sep 14, 2026 | neutral | 0 | 0.6 |
| LPCN Forecast — Price Target — Prediction for 2027 - TradingView | LPCN Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| $LPCN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative | $LPCN stock is up 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 13, 2026 | neutral | 0 | 0.6 |
| Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com | Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 Investing.com | View source ↗ | Investing.com | Apr 6, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.